| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -29.7 | -23.6 |
| EPS (diluted, $ a share) | $-0.67 | $-20.34 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: AVLN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Avalyn Pharma Inc.: key numbers
- Share price
- $29.76Close, Nov 16
- Market cap
- $1.32B
- Shares outstanding
- 44.33MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Avalyn Pharma Inc.
All →Avalyn Pharma 10% Owner Fmr LLC Sells $6.7M of Stock
Fmr LLC, 10% Owner, sold 228,454 shares of Avalyn Pharma Inc. at $29.06 to $30.28 a share (average $29.33) in 4 transactions, worth $6.7M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 2,056,081 (-2.3%).
- Value
- $6.7M
- Shares
- 228,454
- Average price
- $29.33
- Role
- 10% Owner
- Holding change
- -2.3%
- Trade date
- Nov 9, 2026 to Nov 10, 2026
Avalyn Pharma Financial Results
Avalyn Pharma reported financial results for the third quarter of 2026, ending the period with $386.6 million in cash and a runway projected into 2029. The company highlighted clinical progress, including the initiation of a Phase 1 study for its AP03 combination therapy and upcoming Phase 2 data readouts for AP01 and AP02 expected in 2027.
- Term
- Q3 2026
“As we approach year end, I’m proud of the progress we’ve made across our portfolio and the strong foundation we’ve built for what we expect to be a transformational 2027, with data anticipated across all three of our programs.”
Lyn Baranowski, Chief Executive Officer of Avalyn
“We remain confident in the potential of inhaled therapies to transform the standard of care for pulmonary fibrosis by delivering effective, well-tolerated treatments both as monotherapies and in combination.”
Lyn Baranowski, Chief Executive Officer of Avalyn
Avalyn Pharma Leadership Change
Avalyn Pharma Inc. appointed Robert Meyer, M.D. to its Board of Directors as a Class II director, effective September 15, 2026. Dr. Meyer, a former FDA director and Merck executive, brings extensive regulatory and clinical experience to the board. He will receive an annual cash retainer of $40,000 and an initial grant of options to purchase 31,182 shares of common stock.
- Counterparty
- Robert Meyer, M.D.